1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
202.24 USD   +4.00%
08/08BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
08/08Nomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
08/08Nomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene Shares Drop 12% After Deal to License InnoRNA Technology

07/06/2022 | 12:38pm EDT

By Chris Wack


BeiGene Ltd. shares fell 12% to $171.90 after the company said it entered into a worldwide strategic collaboration with InnoRNA to use its technology platform for developing mRNA-based therapeutics.

InnoRNA will receive an upfront cash payment and will be eligible to receive additional payments based upon the achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties, for the mRNA-LNP research collaboration programs.

BeiGene will hold exclusive global development and commercialization rights for the mRNA-LNP therapies jointly discovered by InnoRNA and BeiGene.

InnoRNA will receive an additional upfront cash payment and is eligible for additional milestone payments for granting BeiGene non-exclusive license to its proprietary LNP Technology platform.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

07-06-22 1237ET

All news about BEIGENE, LTD.
08/08BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/08Nomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
08/08Nomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
08/05WALL STREET STOCK EXCHANGE : Another case of good news is bad news
MS
08/05ANALYST RECOMMENDATIONS : Eli Lilly, KLA, Kellogg, Epam Systems, BeiGene...
MS
08/05BeiGene Shares Gain After Doubling of Second-Quarter Revenue
DJ
08/04BeiGene Q2 Net Loss per ADS Widens as Revenue Rises; Shares Surge
MT
08/04BEIGENE : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/04Earnings Flash (BGNE) BEIGENE Posts Q2 Revenue $341.6M
MT
08/04BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 394 M - -
Net income 2022 -1 619 M - -
Net cash 2022 2 960 M - -
P/E ratio 2022 -16,6x
Yield 2022 -
Capitalization 20 926 M 20 926 M -
EV / Sales 2022 12,9x
EV / Sales 2023 9,06x
Nbr of Employees 8 500
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 202,24 $
Average target price 275,30 $
Spread / Average Target 36,1%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-25.35%20 926
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.64%40 375